Our results, combined with the fact that serum AST and ALT are widely and rapidly available, easy to interpret, low-cost biomarkers, suggest a possible role for AST/ALT ratio in the identification of PM/DM-ILD patients at increased risk of adverse outcomes that may need early intensive management. The gene discussed is GPT; the disease is dermatomyositis.